News / Events

Spain’s Pharmaceutical Financing Committee Focuses on Increasing Competition, Strengthening Therapeutic Positioning Reports

Region: EUROPE | Type: Policy | Keywords: #biosimilars #capf #drugevaluation #generics #hta #innovation #irp #newindications #pricesetting #referencepricing #therapeuticpositioningreports

  • The Advisory Committee for the Financing of Pharmaceutical Provisions (CAPF) under the National Health Service (SNS) has put forth a series of proposals to address, in the medium term, the pricing and financing strategies of medicines in Spain
  • The below plan for CAPF will be addressed over the next two years
  • In no particular order, CAPF is focusing on promoting increased competition, revising the criteria for pricing and reimbursing new medicines and indications, improving Spain’s therapeutic positioning reports, and developing a dynamic evaluation system that considers not only new medicines but also those with a high degree of uncertainty


MADRID, Spain – The Advisory Committee for the Financing of Pharmaceutical Provisions (CAPF) under the National Health Service (SNS) supports the progress being made regarding public financing and the pricing of pharmaceuticals in Spain but believes the practices related to these issues need a boost.

As such, CAPF has put forth a series of proposals to address, in the medium term, the pricing and financing strategies of medicines, in line with practices in other advanced countries. The committee believes these measures should be adopted as they are of “the utmost importance” when it comes to the efficiency and sustainability of Spain’s health system.

The below plan for CAPF will be addressed over the next two years.

First, Spain needs qualified personnel to carry out a review of the pricing and financing of medicines, with consideration of technical recommendations. This will require a survey of technical resources in the country.

To promote increased price competition in Spain, CAPF is calling for a review of the current reference price system, specifically its strengths and weaknesses. There is a need for other analyses, including of auctioning, joint purchasing, centralized purchasing, transparency measures, and prescription by active ingredient, as well.

Spain should zero in on competition between active ingredients with similar therapeutic activity and find alternatives for the entry pricing of generics and biosimilars, with the aim of increasing competition in this area.

CAPF also considered price setting criteria and procedures for financing new medicines and indications. The committee is promoting analysis of price setting mechanisms, especially how incremental clinical benefit and incremental cost-effectiveness ratios are accounted for when it comes to therapeutic reports for new medicines or indications.

Likewise, this entails an analysis of the criteria for inclusion of the medicine in the SNS, as well as coverage of new indications. The analysis should extend to medicines granted conditional marketing authorization by the European Medicines Agency (EMA) and how to finance them.

CAPF will issue recommendations for medicines with a high degree of uncertainty, safety, and efficacy and, separately, suggestions for setting costs per QALY, which can be used for pricing and financing decisions. Going forward, there should be a way for medicines to be evaluated once more data become available.

With the review of pricing and financing decisions in mind, CAPF has also suggested improvements to therapeutic positioning reports. This would entail developing tools for the evaluation of incremental clinical benefit and cost-effectiveness ratios for a medicine’s indication(s) and budget impact, and how to incorporate efficiency in therapeutic positioning reports.

Lastly, CAPF wants to ensure the development of a dynamic evaluation system in Spain. For this to come into fruition, CAPF aims to produce guidelines for the monitoring of results from managed entry agreements (MEAs), define the criteria to evaluate the health outcomes of high-priced medicines, set criteria for the review of prices at launch and upon biosimilar or generic competition, review criteria for the pricing of new indications of a medicine, and assess the criteria for reviewing the pricing and reimbursement status of a medicine when new information of efficacy and cost-effectiveness arise.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.

NHIS-Commissioned Study Finds Generic Medicines Used Less in South Korea Compared to OECD Countries

Country: SOUTH KOREA | Region: ASIA & SOUTH PACIFIC | Type: Policy | Keywords: #domesticproduction #drugsupply #genericdruguse #generics #krpia #nhis #oecd #pricecuts #regulation PRICENTRIC BRIEF: Head researcher Professor Lee Sang-won of the National Health Insurance Service (NHIS)-commissioned project, “Improvement of Drug Supply and Purchasing System,” has expressed support for South Korean health policy to lower generic drug prices and expand their use Generics in OECD countries comprise 70% of total […]

Merck’s Keytruda Secures Metastatic Colorectal Cancer Approval from FDA

Country: UNITED STATES | Region: NORTH AMERICA | Type: Drug Approval | Keywords: #fda #merck #msd #oncologycenterofexcellence #projectorbis #realtimeoncologyreview #rtor PRICENTRIC BRIEF: The U.S. Food and Drug Administration (FDA) has approved Merck’s Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer Approval from the FDA is based on results from the Phase 3 KEYNOTE-177 trial […]

ICER’s 2020 Unsupported Price Increase Analysis Will Focus on 13 Drugs

Country: UNITED STATES | Region: NORTH AMERICA | Type: Cost Effectiveness | Keywords: #clinicalevidence #icer #prescriptiondrugs #pricechanges #priceincreases PRICENTRIC BRIEF: The Institute for Clinical and Economic Review (ICER) published its protocol for its upcoming “Unsupported Price Increase” (UPI) report in which the institute will examine significant price increases for prescription drugs and determine if new evidence is needed to support the increases ICER’s report will focus on up […]

UK Launches “Pioneering” Payment Scheme to Tackle AMR

Country: UNITED KINGDOM | Region: EUROPE | Type: Policy | Keywords: #amr #antibiotics #antimicrobialresistance #incentive #innovation #model #payment #subscription #uk PRICENTRIC BRIEF: In a world-first, the UK is testing a pioneering scheme to provide new antibiotics to NHS patients by offering to pay pharmaceutical companies upfront for their contributions As part of the project, the NHS is offering two contracts to pay pharmaceutical companies at the start of their work for access […]

Spain Must “Go Further, Bet on R&D, Innovation, Knowledge,” Says Farmaindustria President Sellés

Country: SPAIN | Region: EUROPE | Type: Policy | Keywords: #access #affordability #clinicaltrials #covid19 #farmaindustria #industry #investment #r&d #sns PRICENTRIC BRIEF: In its pharmaceutical industry proposals for economic and social reform, the National Trade Association of the Spanish-Based Pharmaceutical Industry (Farmaindustria) is requesting more investment in research and production in Spain Sellés explained that investment in R&D and innovation and public-private collaboration are crucial to be “faster in finding pharmacological and more […]

Japan Pharma Association Introduces Bold Policy Measures to Reform Sector

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Policy | Keywords: #covid19 #drugsupply #innovation #jpma #marketentryrewards #mhlw #patientaccess #pharmasector #r&d #re-pricing #regulation #taxincentives #vaccines PRICENTRIC BRIEF: The Japan Pharmaceutical Manufacturers Association (JPMA) has proposed a new policy for economic and fiscal management and reform in Japan, which was mainly inspired by the effect of the coronavirus pandemic on the healthcare system and pharmaceutical industry in Japan The proposal first addresses the immediate need of […]

FDA Approves BMS’ Opdivo for Advanced ESCC After Chemotherapy

Country: UNITED STATES | Region: NORTH AMERICA | Type: Drug Approval | Keywords: #bms #escc #esophagealcancer #fda #priorityreview PRICENTRIC BRIEF: The U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), following prior fluoropyrimidine- and platinum-based chemotherapy Approval from the U.S. regulator is based on results from […]

Greece Pharma Association Puts Forth 7 Pillars to Boost Sector

Country: GREECE | Region: EUROPE | Type: Policy | Keywords: #healthsystem #sfee PRICENTRIC BRIEF: The Hellenic Association of Pharmaceutical Companies (SFEE) has put forth a proposal consisting of seven pillars to lead to a sustainable and efficient health system and pharmaceutical sector in Greece The seven pillars address the pharmaceutical budget, the efficiency of the health system in Greece, clawback payments, patient access to innovation, […]

Canada Publishes Budget Impact Analysis Guidelines Under New PMPRB Amendments

Country: CANADA-ONTARIO | Region: NORTH AMERICA | Type: Policy | Keywords: #budgetimpactanalysis #cadth #guidelines #newdrug #pmprb #referencepricing #reimbursement PRICENTRIC BRIEF: The Government of Canada has published “Budget Impact Analysis Guidelines” for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada, as part of the new amendments to the Patented Medicine Prices Review Board (PMPRB) Budget impact analyses (BIAs) will focus on the financial impact of a […]